Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.

Cobo M, Gutiérrez V, Villatoro R, Trigo JM, Ramos I, López O, Ruiz M, Godoy A, López I, Arroyo M.

Lung Cancer (Auckl). 2017 Jul 12;8:57-66. doi: 10.2147/LCTT.S118996. eCollection 2017. Review.

2.

Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy.

Gomez-Millan J, Pajares B, Perez-Villa L, Carnero A, Alvarez M, De Luque V, Rivas F, Trigo JM, Toledo MD, Alba E, Medina JA.

BMC Cancer. 2016 Oct 28;16(1):829.

3.

The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.

Gueye AB, Pryslawsky Y, Trigo JM, Poulia N, Delis F, Antoniou K, Loureiro M, Laviolette SR, Vemuri K, Makriyannis A, Le Foll B.

Int J Neuropsychopharmacol. 2016 Dec 30;19(12). pii: pyw068. doi: 10.1093/ijnp/pyw068. Print 2016 Dec.

4.

Screening Medications for the Treatment of Cannabis Use Disorder.

Panlilio LV, Justinova Z, Trigo JM, Le Foll B.

Int Rev Neurobiol. 2016;126:87-120. doi: 10.1016/bs.irn.2016.02.005. Epub 2016 Mar 10. Review.

5.

Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, Barnes AJ, Huestis MA, Le Foll B.

Drug Alcohol Depend. 2016 Apr 1;161:298-306. doi: 10.1016/j.drugalcdep.2016.02.020. Epub 2016 Feb 23.

6.

Effects of various cannabinoid ligands on choice behaviour in a rat model of gambling.

Gueye AB, Trigo JM, Vemuri KV, Makriyannis A, Le Foll B.

Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):258-69. doi: 10.1097/FBP.0000000000000222.

7.

Role of the endogenous cannabinoid system in nicotine addiction: novel insights.

Gamaleddin IH, Trigo JM, Gueye AB, Zvonok A, Makriyannis A, Goldberg SR, Le Foll B.

Front Psychiatry. 2015 Mar 25;6:41. doi: 10.3389/fpsyt.2015.00041. eCollection 2015. Review.

8.

5-HT2C receptor desensitization moderates anxiety in 5-HTT deficient mice: from behavioral to cellular evidence.

Martin CB, Martin VS, Trigo JM, Chevarin C, Maldonado R, Fink LH, Cunningham KA, Hamon M, Lanfumey L, Mongeau R.

Int J Neuropsychopharmacol. 2014 Oct 31;18(3). pii: pyu056. doi: 10.1093/ijnp/pyu056.

9.

Thyroid cancer: SEOM clinical guidelines.

Trigo JM, Capdevila J, Grande E, Grau J, Lianes P; Spanish Society for Medical Oncology.

Clin Transl Oncol. 2014 Dec;16(12):1035-42. doi: 10.1007/s12094-014-1224-4. Epub 2014 Sep 23.

10.

Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach.

Le Foll B, Pushparaj A, Pryslawsky Y, Forget B, Vemuri K, Makriyannis A, Trigo JM.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:86-93. doi: 10.1016/j.pnpbp.2013.10.009. Epub 2013 Oct 17. Review.

11.

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.

Fumoleau P, Trigo JM, Isambert N, Sémiond D, Gupta S, Campone M.

BMC Cancer. 2013 Oct 7;13:460. doi: 10.1186/1471-2407-13-460.

12.

Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.

Pajares B, Trigo JM, Toledo MD, Álvarez M, González-Hermoso C, Rueda A, Medina JA, de Luque V, Jerez JM, Alba E.

BMC Cancer. 2013 Jan 18;13:26. doi: 10.1186/1471-2407-13-26.

13.

Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB₂ receptors.

Aracil-Fernández A, Trigo JM, García-Gutiérrez MS, Ortega-Álvaro A, Ternianov A, Navarro D, Robledo P, Berbel P, Maldonado R, Manzanares J.

Neuropsychopharmacology. 2012 Jun;37(7):1749-63. doi: 10.1038/npp.2012.22. Epub 2012 Mar 14.

14.

Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.

Elhabazi K, Trigo JM, Mollereau C, Moulédous L, Zajac JM, Bihel F, Schmitt M, Bourguignon JJ, Meziane H, Petit-demoulière B, Bockel F, Maldonado R, Simonin F.

Br J Pharmacol. 2012 Jan;165(2):424-35. doi: 10.1111/j.1476-5381.2011.01563.x.

15.

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.

Vermorken JB, Guigay J, Mesia R, Trigo JM, Keilholz U, Kerber A, Bethe U, Picard M, Brummendorf TH.

Br J Cancer. 2011 May 24;104(11):1691-6. doi: 10.1038/bjc.2011.152. Epub 2011 May 3.

16.

Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Berrendero F, Robledo P, Trigo JM, Martín-García E, Maldonado R.

Neurosci Biobehav Rev. 2010 Nov;35(2):220-31. doi: 10.1016/j.neubiorev.2010.02.006. Epub 2010 Feb 16. Review.

17.

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J; Spanish Society of Medical Oncology.

Ann Oncol. 2010 Feb;21(2):195-8. doi: 10.1093/annonc/mdp595. No abstract available.

18.

Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin.

Trigo JM, Zimmer A, Maldonado R.

Neuropharmacology. 2009 Jun;56(8):1147-53. doi: 10.1016/j.neuropharm.2009.03.013. Epub 2009 Apr 17.

19.

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.

O'Donnell A, Padhani A, Hayes C, Kakkar AJ, Leach M, Trigo JM, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I.

Br J Cancer. 2005 Oct 17;93(8):876-83.

20.

Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.

Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Gómez C, Perea S, Ruiz A, Hitt R, Cortés-Funes H.

Antimicrob Agents Chemother. 1997 May;41(5):1175-7.

Supplemental Content

Loading ...
Support Center